Loading data...
Psilocybin-Research.com Searchable psilocybin and psilocin bibliometric database.

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

Research workflow

Search, filter, export, analyze, and monitor psilocybin and psilocin publications with source labels, publication status, citation links, alerts, API access, and full SQLite download.

Databases used

  • PubMed
  • Crossref
  • Europe PMC
  • OpenAlex
  • medRxiv
  • bioRxiv
  • PsyArXiv
  • ClinicalTrials.gov

Psilocybin and psilocin research index

Find psilocybin and psilocin papers, preprints, trials, and citations with clear source context.

Database 4,054 indexed records
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Database 4,054 indexed records
4,054 Total Publications 3,914 Psilocybin Records 569 Psilocin Records 569 Search Matches 826 Journals 66 Research Topics
Published 3,317 Peer-reviewed / formal records
Preprints 450 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
PubMed 278 6.9% Active
Europe PMC 1,652 40.7% Active
OpenAlex 1,401 34.6% Active
ClinicalTrials.gov 287 7.1% Active
PsyArXiv 191 4.7% Active
bioRxiv 142 3.5% Active
Crossref 69 1.7% Active
Publication timeline 3,041 dated records
3,041 records since 2020
Annual records Cumulative line
Default publication index

Latest publications

569 records from the full SQLite publication database, sorted by newest first.

Result settings and export data
Updated Jul 5, 2026 01:22 UTC
Checking for newly indexed publications...
Page 8 of 29

Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (Psilocybe cubensis): A Systematic Review.

Psilocybin, a major indole alkaloid found in magic mushrooms (Psilocybe cubensis), has recently drawn attention as a breakthrough therapy to treat major depressive disorder. This review aimed to summarize and identify knowledge gaps concerning their pharmacokinetic characteristics of psilocybin and its active metabolite, psilocin. Original studies related to...

Unknown journal 2024-09-09 Thaoboonruang N, Lohitnavy M, Lohitnavy O.

The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.

Emerging evidence suggests that classical psychedelics possess immunomodulatory and anti-inflammatory properties; however, these effects are yet to be well-established. This systematic review aims to provide a timely and comprehensive overview of the immunomodulatory effects of classical psychedelics in preclinical studies. A systematic search was conducted ...

Unknown journal 2024-09-06 Low ZXB, Ng WS, Lim ESY, Goh BH, Kumari Y.

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.

Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut mic...

Rapidly Trading Down Depression's 3 Pillars to 5HT3-Receptors Through ECT or Psilocybin?

Depression astonishingly can be stopped instantly by electrotherapies or through some psychedelics like psilocybin. In explaining this, the traditional approaches to their antidepressant effects via "reset" models and orthosteric serotonin receptors has neglected the only serotonin channel 5HT3, which e.g. has emerged as being helpful for the neurotrophic tr...

Unknown journal 2024-08-31 Treviranus GRS.

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting

Background Recent studies have intensively explored the potential antidepressant effects of psilocybin. However, important variables such as previous experience, repeated administration, setting and sex remain underexplored. This study describes the acute psilocybin experience and long-term effects in a small sample of healthy individuals. Methods In a doubl...

­­­­Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study

Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects a single dose have not been investigated. Aims To investigate the pharmacokinetics, feasibility, safety, and efficacy of single-dose psil...

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium

Background: Recent evidence suggests that psychedelics are able to induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for these traits is the phenomenon of neuroplasticity, although exact underlying molecular mechanisms remain unclear. Aims: This study investigates selected neuroplastic effects of psilocin, lysergic ...

PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin

Post-Traumatic Stress Disorder (PTSD) is a debilitating mental health condition that can occur after experiencing or witnessing a traumatic event. The impact of PTSD extends beyond the individual, affecting families, communities, and society as a whole. This study aims to investigate the potential of psilocybin as a treatment for PTSD. Psilocybin, after bein...

Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα

SUMMARY The 5HT 2A receptor (5HT 2A R) is a G protein-coupled receptor that drives many neuronal functions and is one of the primary targets for psychedelic drugs, which have recently shown promise in treating mental disorders. Understanding ligand interactions and conformational transitions is essential for developing effective pharmaceuticals, but mechanis...

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate...

Psilocybin for the treatment of Alzheimer's disease.

Alzheimer's disease (AD) stands as a formidable neurodegenerative ailment and a prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency for innovative treatment modalities. Psilocybin, a psychoactive alkaloid intrinsic to hallucinogenic mushrooms, has garnered attention within the neuropsychiatric realm due to i...

Unknown journal 2024-07-09 Zheng S, Ma R, Yang Y, Li G.

Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method

Psilocybin is a psychedelic compound found in some hallucinogenic "magic mushrooms". Psilocin is the active metabolite of Psilocybin, and it is the subject of several studies for the treatment of psychological disorders, such as anxiety, depression, and post-traumatic stress disorder. As such, the pharmacokinetic properties of psilocin should be evaluated to...

Mushroom poisoning of Panaeolus subbalteatus from Ningxia, northwest China, with species identification and tryptamine detection.

Mushroom poisoning is a significant contributor to foodborne disease outbreaks in China. This study focuses on two Panaeolus subbalteatus poisoning incidents accompanied by epidemiological investigations, species identification, and toxin detection in Ningxia, northwest China. In these two poisoning incidents, some patients exhibited gastrointestinal or neur...

Unknown journal 2024-07-03 Yao Y, Zhang YZ, Liang JQ, Liu F, Li ZF, Li HJ

Historical Perspectives and Pharmacodynamic Actions of the Magic Mushroom (Psilocybin) for Future Global Healthcare

Many medicines and treatments for varying levels of ailments were found through natural bioactives before complex separation techniques were available.Ironically, as medicine advances, drastically more people seem to be reverting to a desire for these natural bioactives.Due to this, it is important to discover and research the pharmacology of historically us...

Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders

This study is a two-group feasibility study of oral psilocybin combined with a 12-week group-based program, customized for firefighters. Trained facilitators will help create a trauma-informed space for the group (n = 6-8) to thrive and promote cognitive resilience. The topics covered throughout the 12 weeks include breath-work, mindfulness, self-compassion,...

Increased 5-HT2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics

ABSTRACT Background and Purpose Serotonergic psychedelic drugs are under renewed investigation for the potential treatment of several psychiatric disorders. While all serotonergic psychedelics have 5-HT2A receptor activity, the explanation for why some 5-HT2A receptor agonists are not psychedelic is unknown. To address this question, we investigated the 5-HT...

Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans

Several fungi belonging to the genus Psilocybe, also called “magic mushrooms”, contain the hallucinogenic drugs psilocybin and psilocin. They are chemically related to serotonin (5-HT). In addition to being abused as drugs, they are now also being discussed or used as a treatment option for depression. Here, we hypothesized that psilocybin and psilocin may a...

The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin.

Psilocin, or 4-HO-DMT (or 3-(2-dimethylaminoethyl)-1H-indol-4-ol), is a psychoactive alkaloid substance from the tryptamine family, isolated from Psilocybe mushrooms. This substance is being studied by various research groups because it has a clear therapeutic effect in certain dosages. In this work, the study of the structure and properties of psilocin was ...

Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms

Background and Purpose Demand for new antidepressants has resulted in a re-evaluation of the therapeutic potential of psychedelic drugs. Several tryptamines found in psilocybin-containing “magic” mushrooms share chemical similarities with psilocybin. Early work suggests they may share biological targets. However, few studies have explored their pharmacologic...

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia

BACKGROUND AND AIMS: Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their clinical use. The current study aimed to (1) determine the circumstances of death and case characteristics of LSD- and psilocybin-related death in Australia, 2000-23; and (2) determine the toxicological profile and major...

Live source coverage

4,054 indexed records across 8 active sources.

3,317Published
450Preprints
287Clinical trials
  1. PubMed 278 records · 6.9%
  2. Europe PMC 1,652 records · 40.7%
  3. OpenAlex 1,401 records · 34.6%
  4. ClinicalTrials.gov 287 records · 7.1%
  5. PsyArXiv 191 records · 4.7%
  6. bioRxiv 142 records · 3.5%
  7. Crossref 69 records · 1.7%
  8. medRxiv 34 records · 0.8%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.